[go: up one dir, main page]

BRPI0112407B8 - uso de cepas de parapoxvírus ovis para produzir medicamentos antivirais e medicamentos contra câncer - Google Patents

uso de cepas de parapoxvírus ovis para produzir medicamentos antivirais e medicamentos contra câncer

Info

Publication number
BRPI0112407B8
BRPI0112407B8 BRPI0112407A BRPI0112407B8 BR PI0112407 B8 BRPI0112407 B8 BR PI0112407B8 BR PI0112407 A BRPI0112407 A BR PI0112407A BR PI0112407 B8 BRPI0112407 B8 BR PI0112407B8
Authority
BR
Brazil
Prior art keywords
ovis
cancer drugs
strains
parapoxvirus
produce antiviral
Prior art date
Application number
Other languages
English (en)
Inventor
Knorr Andreas
Siegling Angela
Hirth-Dietrich Claudia
Theiss Gudrun
Volk Hans-Dieter
Weber Olaf
Schlapp Tobias
Original Assignee
Aicuris Gmbh & Co Kg
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co Kg, Bayer Ag filed Critical Aicuris Gmbh & Co Kg
Priority claimed from PCT/EP2001/007991 external-priority patent/WO2002004002A2/de
Publication of BR0112407A publication Critical patent/BR0112407A/pt
Publication of BRPI0112407B1 publication Critical patent/BRPI0112407B1/pt
Publication of BRPI0112407B8 publication Critical patent/BRPI0112407B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"uso de cepas de parapoxvírus ovis para produzir medicamentos antivirais e medicamentos contra câncer". a invenção refere-se ao uso de cepas do vírus parapox ovis como terapia imune para fraquezas imunes infecciosas ou não-infecciosas, assim como o uso de cepas do referido vírus para tratar doenças tumorais e infecções virais. a invenção também refere-se ao uso de cepas do vírus parapox ovis, para produzir medicamentos, tanto para seres humanos, como para animais.
BRPI0112407-2 2000-07-11 2001-07-11 uso de cepas de parapoxvírus ovis para produzir medicamentos antivirais e medicamentos contra câncer BRPI0112407B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10033582.9 2000-07-11
DE10033582 2000-07-11
DE10122451A DE10122451A1 (de) 2000-07-11 2001-05-09 Verwendung von Stämmen des Parapoxvirus ovis zur Herstellung von antiviralen Arzneimitteln und Arzneimitteln gegen Krebs
DE10122451.6 2001-05-09
PCT/EP2001/007991 WO2002004002A2 (de) 2000-07-11 2001-07-11 Verwendung von stämmen des parapoxvirus ovis zur herstellung von antiviralen arzneimitteln und arzneimitteln gegen krebs

Publications (3)

Publication Number Publication Date
BR0112407A BR0112407A (pt) 2003-07-22
BRPI0112407B1 BRPI0112407B1 (pt) 2019-02-12
BRPI0112407B8 true BRPI0112407B8 (pt) 2021-05-25

Family

ID=7648486

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0112407-2 BRPI0112407B8 (pt) 2000-07-11 2001-07-11 uso de cepas de parapoxvírus ovis para produzir medicamentos antivirais e medicamentos contra câncer

Country Status (12)

Country Link
JP (1) JP2012121902A (pt)
KR (1) KR100805996B1 (pt)
BR (1) BRPI0112407B8 (pt)
DE (1) DE10122451A1 (pt)
DO (1) DOP2001000211A (pt)
EC (1) ECSP034419A (pt)
GT (1) GT200100136A (pt)
HN (1) HN2001000154A (pt)
PE (1) PE20020187A1 (pt)
SV (1) SV2002000528A (pt)
TW (1) TWI304341B (pt)
ZA (1) ZA200300274B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023083950A1 (en) * 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with immunomodulators
WO2023083943A1 (en) * 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with antivirals

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714665A1 (de) * 1977-04-01 1978-10-05 Mayr Anton Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN1217751A (zh) * 1996-03-29 1999-05-26 奥塔戈大学 副痘病毒载体
AU775956B2 (en) * 1998-11-02 2004-08-19 Otago Innovation Limited Vascular endothelial growth factor-like protein from ORF virus NZ2 binds and activates mammalian VEGF receptor-2

Also Published As

Publication number Publication date
KR20030016387A (ko) 2003-02-26
ECSP034419A (es) 2003-03-10
TWI304341B (en) 2008-12-21
KR100805996B1 (ko) 2008-02-26
SV2002000528A (es) 2002-10-24
GT200100136A (es) 2002-07-03
HN2001000154A (es) 2001-09-21
DOP2001000211A (es) 2002-12-15
BR0112407A (pt) 2003-07-22
BRPI0112407B1 (pt) 2019-02-12
DE10122451A1 (de) 2002-04-04
JP2012121902A (ja) 2012-06-28
ZA200300274B (en) 2004-01-22
PE20020187A1 (es) 2002-05-19

Similar Documents

Publication Publication Date Title
ATE500808T1 (de) Onkolytische virustherapie
SE0300034D0 (sv) Use of strains of the parapox ovis virus for producting antiviral pharmaceuticals and anticancer pharmaceuticals
EA200100302A1 (ru) Способы и композиции для протективной и терапевтической генетической иммунизации
WO1996005866A3 (de) Lebendvakzine zur behandlung von tumorerkrankungen
WO2001055111A8 (en) Biaryl compounds, their preparation and their use in therapy
BRPI0112407B8 (pt) uso de cepas de parapoxvírus ovis para produzir medicamentos antivirais e medicamentos contra câncer
BR0109928A (pt) Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal
EP1218011A4 (en) 3-HYDROXY-4-PYRON GALLIUM COMPLEXES FOR THE TREATMENT OF INFECTIONS WITH INTRACELLULAR PROKARYOTS, DNA VIRUSES AND RETROVIRUSES
BR9913990A (pt) Uso de compostos organofosforados para a produção de preparações farmacêuticas para o tratamento terapêutico e profilático de infecções ou como um fungicida, bactericida ou herbicida em plantas
DE60127965D1 (de) Nachweis viraler agentien in brustmilchkanälen und antivirale therapie
LT2003008A (en) Parapox ovis virus for use against organ fibrosis
EA199800770A1 (ru) Лекарственный препарат для терапевтического лечения вирусного гепатита
DK1196439T3 (da) Forbindelser udvisende en antibiotikaaktivitet
DK1150981T3 (da) Terapeutisk necleosidforbindelse
DE60228687D1 (de) Cyanoacrylat-zusammensetzungen für die therapeutische behandlungvon wunden, die eine revision erfordern
RU2002118650A (ru) Штамм № 1737/Грузия/2000 вируса ящура типа Азия-1 для изготовления диагностических и вакцинных препаратов
DE69803052D1 (de) Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt
Okamoto The 44th Scientific Meeting: Perspectives of Internal Medicine: Virology for Physician∼ Recent Advance in Viral Infection and Treatment∼: 3. Common Viral Infectious Diseases; Viral Hepatitis: 3) Hepatitis A and E
AU2001274661A1 (en) Therapeutic vaccine preparation and treatment for hiv viral infection
UA43484A (uk) Спосіб індукції інтерферону

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: AICURIS GMBH AND CO. KG (DE)

Free format text: TRANSFERIDO DE: BAYER AKTIENGESELLSCHAFT

B25G Requested change of headquarter approved

Owner name: AICURIS GMBH AND CO. KG (DE)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070107873/RJ DE 03/08/2007.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/02/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/02/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/07/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2678 DE 03-05-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.